Evidence map›Paper›PMID 32514618›Full record

ArticleCancer immunology, immunotherapy : CII2020

CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment.

Chao Xin, Jianmin Zhu, Song Gu, Minzhi Yin, Jing Ma, Ci Pan, Jingyan Tang, Peng Zhang, Yang Liu, Xue-Feng Bai and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma.European journal of cancer (Oxford, England : 1990) · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Review
  17. Translational cancer research · 2022
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Chao XinPediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianmin ZhuPediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Song GuDepartment of General Surgery/Surgical Oncology Center, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dong Fang Road, Pu Dong New District, Shanghai, 200017, China.
Minzhi YinDepartment of Pathology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing MaDepartment of Pathology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ci PanDepartment of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dong Fang Road, Pu Dong New District, Shanghai, 200127, China.
Jingyan TangDepartment of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dong Fang Road, Pu Dong New District, Shanghai, 200127, China.
Peng ZhangDivision of Immunotherapy, Institute of Human Virology, University of Maryland, School of Medicine, Baltimore, MD, 21201, USA.
Yang LiuDivision of Immunotherapy, Institute of Human Virology, University of Maryland, School of Medicine, Baltimore, MD, 21201, USA.
Xue-Feng BaiDepartment of Pathology, College of Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Xi MoPediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Min XuDepartment of General Surgery/Surgical Oncology Center, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dong Fang Road, Pu Dong New District, Shanghai, 200017, China. jackxm1236@126.com.
Hua ZhuPediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhu-hua@scmc.com.cn.ORCID http://orcid.org/0000-0001-6757-2618
Shanghai Jiao Tong University · CNUniversity of Maryland, Baltimore · USThe Ohio State University · US

Funding

National Natural Science Foundation of China 81773039National Natural Science Foundation of China 81800118Science and Technology Commission of Shanghai Municipality 17441903200Science and Technology Commission of Shanghai Municipality (CN) 17411950402
6 · The paper itself

Abstract

Patients with pediatric cancers such as neuroblastoma (NB) are often unresponsive to checkpoint blockade immunotherapy. One major factor in pediatric tumor resistance to immunotherapy is considered to be the low mutation rate of pediatric tumors. Another factor may be the overexpression of additional inhibitory pathways. While analyzing the RNA-sequencing database TARGET, we found that human NB tumors overexpress immune checkpoint molecule CD200. To determine its significance and impact on tumor immune microenvironment, we analyzed 49 cases of previously untreated, surgically removed NB tumors using immunohistochemistry and multi-color flow cytometry (FACS). We found that CD200 is overexpressed in more than 90% of NB tumors. In the tumor microenvironment of NB, CD200 is mainly overexpressed in CD45

Indexed as

Antigens, CDCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChild, PreschoolFemaleHumansInfantLymphocytes, Tumor-InfiltratingMaleNeuroblastomaOrexin ReceptorsTumor EscapeTumor MicroenvironmentAntigens, CDantigens, CD200CD200R1 protein, humanOrexin ReceptorsCD200CD200RNeuroblastomaTumor immune microenvironmentTumor-infiltrating lymphocyte

Identifiers

PMID32514618
PMCPMC11027654
OpenAlexW3033163292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.